Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Conference Call October 30, 2024 9:00 AM ET

Company Participants

David Clair - Vice President-Investor Relations
Kim Kelderman - President and Chief Executive Officer
Jim Hippel - Chief Financial Officer

Conference Call Participants

Puneet Souda - Leerink Partners
Jacob Johnson - Stephens
Dan Leonard - UBS
Thomas DeBourcy - Nephron Research
Justin Bowers - Deutsche Bank
Tom Peterson - Baird
Matt Larew - William Blair
Sung Ji Nam - Scotiabank

Operator

Good morning, and welcome to the Bio-Techne Earnings Conference Call for the First Quarter of Fiscal Year 2025. At this time, all participants have been placed in listen-only mode and the call will be open for questions following management's prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up.

I would now like to turn the call over to David Clair, Bio-Techne's Vice President, Investor Relations.

David Clair

Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne.

Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company's future results.

The company's 10-K for fiscal year 2024 identifies certain factors that could cause the company's actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K, as well as the company's other SEC filings, are available on the company's website within its Investor Relations section.

During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to most comparable GAAP measures are available in the company's press release issued earlier this morning on the Investor Relations section of our Bio-Techne Corporation website at www.bio-techne.com.

Separately, in the coming weeks, we will be participating in the UBS, Stifel, Stephens and Jefferies conferences. We look forward to connecting with many of you at these upcoming events.

I will now turn the call over to Kim.

Kim Kelderman

Thanks, Dave, and good morning, everyone. Thank you for joining us for our first quarter conference call.

I'm pleased to report that the start to our fiscal year 2025 was largely consistent with our initial expectation. Continued stabilization of our biopharma end-markets combined with excellent execution by the Bio-Techne team led to 4% year-over-year organic revenue growth.